The combined detection of CD9, survivin and GFAP markers on the surface of serum-derived exosomes from glioma patients by imaging flow cytometry may provide another useful tool for monitoring tumor status in patients receiving survivin-based immunotherapies. The gene discussed is CD9; the disease is glioma.